Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged
2007 ◽
Vol 51
(8)
◽
pp. 2982-2984
◽
Keyword(s):
ABSTRACT Plasma ketoconazole (KETO), amprenavir (APV), and ritonavir (RTV) pharmacokinetics were evaluated in 15 healthy subjects after being treated with KETO at 200 mg once daily (QD), fosamprenavir (FPV)/RTV at 700/100 mg twice daily (BID), and then KETO at 200 mg QD plus FPV/RTV at 700/100 mg BID in this open-label study. The KETO area under the concentration-time curve at steady state was increased 2.69-fold with FPV/RTV. APV exposure was unchanged, and RTV exposure was slightly increased.
1999 ◽
Vol 43
(5)
◽
pp. 1152-1155
◽
Keyword(s):
2014 ◽
Vol 4
(4)
◽
pp. 256-261
◽
Keyword(s):
Keyword(s):
Keyword(s):
2006 ◽
Vol 50
(7)
◽
pp. 2309-2315
◽
Keyword(s):